Brinker Harding’s Campaign Focuses on Drug Price Reforms Amid Pharma Investments
Omaha city councilor and Congressional candidate for Nebraska’s 2nd District, Brinker Harding, is advocating for significant changes in pharmaceutical pricing, despite holding substantial financial stakes in the industry. Harding, a Republican, is challenging Democratic contender Denise Powell, a small business owner, in the upcoming election.
On August 4, Harding released a video on social media emphasizing that “Nebraskans deserve affordable health care,” while backing a most-favored nation policy aimed at reducing drug prices. This approach, initially promoted by President Donald Trump, seeks to align Medicaid drug payments with prices in other nations, potentially saving the federal government billions, according to the White House. However, critics argue that such measures may not effectively diminish the pharmaceutical sector’s influence on drug pricing or decrease consumer costs.
In a January op-ed published in the Omaha World-Herald, Harding reiterated his stance, expressing a desire to halt “subsidizing big pharma and big insurance with taxpayer-funded bailouts.” Despite these assertions, financial disclosures reveal that Harding and his spouse possess investments ranging up to $125,000 in leading pharmaceutical giants Pfizer and AbbVie. Both corporations have faced legal actions for price inflation and alleged profiteering.
While Pfizer and AbbVie had previously agreed to a voluntary most-favored nation pricing model with the Trump administration, both companies proceeded to increase drug prices in 2026.
Healthcare affordability remains a pivotal topic this election season. Denise Powell, Harding’s opponent, is advocating for a nationwide cap on insulin costs at $35 per month for all Americans.
The post Brinker Harding has up to $125,000 invested in Big Pharma appeared first on American Journal News.
—
Read More Kitchen Table News
Comments are closed.